Lv41
470 积分 2022-11-04 加入
SUCCINCT: An Open-label, Single-arm, Non-randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-line Treatment for Patients with Advanced Urothelial Carcinoma
3小时前
待确认
Randomized phase III trial of eribulin (E) versus standard weekly paclitaxel (P) as first- or second-line therapy for locally recurrent or metastatic breast cancer (MBC)
19天前
已关闭
Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models
19天前
已完结
Microtubules as a target for anticancer drugs
19天前
已完结
How Do Microtubule-Targeted Drugs Work? An Overview
20天前
已完结
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth
20天前
已完结
Induction of Morphological and Biochemical Apoptosis following Prolonged Mitotic Blockage by Halichondrin B Macrocyclic Ketone Analog E7389
20天前
已完结
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
20天前
已完结
Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification
21天前
已完结
皖公网安备34019202002308
